RNF13 is a novel interactor of iduronate 2-sulfatase that modifies its glycosylation and maturation

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
Full text 2,452 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare and fatal disease caused by mutations in the iduronate 2-sulfatase (IDS) encoding gene. The enzymatically inactive variant proteins lead to pathological accumulation of glycosaminoglycans in the lysosomes, causing dysfunction in multiple organs. IDS is expressed as a precursor protein, and its processing and lysosomal targeting are crucial for proper enzymatic activity. However, IDS intracellular dynamic is poorly understood and a better understanding of its processing mechanisms would benefit the development of new therapeutic strategies. AlphaFold 3 predicted an interaction between IDS and the E3 ubiquitin ligase RNF13. Co-immunoprecipitation assays confirm this interaction and further show that RNF13 interacts preferentially with a predominantly underglycosylated immature form of IDS, resulting in altered IDS glycosylation and maturation. The results demonstrate that IDS glycosylation site Asn246 is important for lysosomal targeting, although its glycosylation is not altered by RNF13. This study also unravels that RNF13 forms a heterodimer with the E3 ubiquitin ligase RNF167 that modify both RNF13 and RNF167 lysosomal trafficking. In addition, the heterodimer interacts and alters IDS differently than RNF13 or RNF167 alone. RNF13 catalytic E3 ligase activity is required to generate an underglycosylated form, but not that of RNF167. This study exposes that the proteasome rapidly degrades IDS underglycosylated forms, and RNF13 exerts a protective effect. Overall, this study reveals a novel and dual role of RNF13 on IDS maturation and degradation, providing mechanistic insights into IDS trafficking. Competing Interest Statement The authors have declared no competing interest. - ABBREVIATIONS - AP - Adaptor protein; - CHX - Cycloheximide; - CQ - Chloroquine; - DN - Dominant negative; - EGAD - Endosome and Golgi-associated degradation; - Endo H - Endoglycosidase H; - ER - Endoplasmic reticulum; - ERAD, - ER-associated degradation; - GAG - Glycosaminoglycan; - IDS - Iduronate 2-sulfatase; - M6P - Mannonse-6-phosphate; - M6PR - M6P receptor; - MOC - Manders’ overlap coefficient - MPS II - Mucopolysaccharidosis type II; - MW - Molecular weight; - PA - Protease-associated; - PNGase F - Peptide:N-glycosidase F; - RING - Really Interesting New Gene; - Tg - Thapsigargin; - TGN - Trans-Golgi Network; - TM - Transmembrane; - Tn - Tunicamycin

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00